How is the CSL (ASX:CSL) share price performing against its sector in 2021?

Can the company's shares stage a rebound towards the backend of this year?

| More on:
Scientists in white coats look disappointed as the Starpharma share price falls today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has failed to outperform the market as opposed to traditional times. The global biotech noted that the pandemic is causing challenging conditions on its business operations.

At the time of writing, CSL shares are fetching for $302.39, down 1.02%.

What's happened to CSL recently?

During mid-August, CSL provided investors with its full-year results for the 2021 financial year.

The company noted that its CSL Behring's portfolio faced headwinds, while its Seqirus business recorded strong tailwinds over the 12 months.

Under the CSL Behring banner, sales of its leading subcutaneous immunoglobulin product, Hizentra, grew by 15%. This contributed to the overall revenue of US$8.8 billion for the CSL Behring portfolio, up 6% on FY20.

CSL's Seqirus business experienced a strong surge in seasonal influenza vaccines, up 41%. A record volume of around 130 million doses was distributed around the world. As a whole, Seqirus revenue jumped to US$1.7 billion, up 30% from the prior corresponding period.

Investors were also updated on the company's plasma collection issues.

CSL noted that federal government stimulus packages from early 2021 had driven down the number of donors per week. This momentarily affected plasma levels before soaring again on the back of vaccine momentum, further marketing initiatives, and a "stimulus burn-off".

As such, plasma collection numbers are down around 20% compared to FY20's levels.

CSL opened 25 new facilities to attract lapsed and new donors through its doors. In FY22, the company plans to open another 40 centres, expanding its presence, mostly across the United States.

How does the CSL share price compare to the Health Care sector?

Over the last 12 months, the CSL share price has moved 7% higher, with year-to-date also up around 6%. The company's shares hit a 52-week high of $320.42 in November 2020, before moving in circles.

In contrast, the S&P/ASX 200 Health Care index (ASX: XHJ) has gained 12% from this time last year and is up 11.5% year-to-date. The sectors also registered a record high of 48,213 points in late August.

Undoubtedly, CSL shares are lagging behind the Health Care Index which has continued to accelerate since March 2020.

Based on today's price, CSL commands a market capitalisation of roughly $137.7 billion, with approximately 455 million shares on issue.

Motley Fool contributor Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »